Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
145.34B
Market cap145.34B
Price-Earnings ratio
19.74
Price-Earnings ratio19.74
Dividend yield
6.68%
Dividend yield6.68%
Average volume
38.31M
Average volume38.31M
High today
$25.87
High today$25.87
Low today
$25.45
Low today$25.45
Open price
$25.73
Open price$25.73
Volume
8.58M
Volume8.58M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$22.09
52 Week low$22.09

Stock Snapshot

The current Pfizer(PFE) stock price is $25.51, with a market capitalization of 145.34B. The stock trades at a price-to-earnings (P/E) ratio of 19.74 and offers a dividend yield of 6.7%.

On 2026-05-15, Pfizer(PFE) stock traded between a low of $25.45 and a high of $25.87. Shares are currently priced at $25.51, which is +0.2% above the low and -1.4% below the high.

The Pfizer(PFE)'s current trading volume is 8.58M, compared to an average daily volume of 38.31M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $22.09.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $22.09.

PFE News

24/7 Wall St. 59m
Michael Burry's Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year. Here Is Why

Michael Burry’s Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year. Here Is Why By Alex Sirois Published May 15, 9:49AM EDT Q...

Michael Burry's Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year. Here Is Why
The Motley Fool 2h
My Top 3 Healthcare Stocks for May 2026

Federal healthcare spending is projected to rise from less than $2 trillion today to more than $3 trillion within a decade, per the Committee for a Responsible...

My Top 3 Healthcare Stocks for May 2026
TipRanks 21h
Pfizer price target raised to $26 from $25 at Wolfe Research

Wolfe Research analyst Alexandria Hammond raised the firm’s price target on Pfizer (PFE) to $26 from $25 and keeps an Underperform rating on the shares followin...

Analyst ratings

54%

of 28 ratings
Buy
35.7%
Hold
53.6%
Sell
10.7%

More PFE News

TipRanks 22h
Pfizer’s New Japan RSV Vaccine Trial Signals Ongoing Expansion for PFE

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

TipRanks 22h
Pfizer’s Prazosin Site-Transfer Trial Signals Quiet but Important Supply-Chain Progress

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

Nasdaq 23h
Pfizer Just Locked In Its Next 5 Years of Growth -- Here's How

Key Points The drugmaker is still nowhere near the heroic financial results it achieved at the height of the pandemic. In fact, it seems to be moving in the w...

Pfizer Just Locked In Its Next 5 Years of Growth -- Here's How
Simply Wall St 2d
Pfizer Hemophilia Drug Win In Europe Adds Weight To Undervalued Thesis

European Commission expands approval for Pfizer's HYMPAVZI (marstacimab) to include adolescents and adults with hemophilia A or B and inhibitors. Decision addr...

Pfizer Hemophilia Drug Win In Europe Adds Weight To Undervalued Thesis
Seeking Alpha 2d
Pfizer granted label expansion for hemophilia therapy Hympavzi in Europe

Pfizer (PFE) announced on Wednesday that the European Commission granted marketing authorization to expand the label of its hemophilia therapy, Hympavzi, to tre...

Pfizer granted label expansion for hemophilia therapy Hympavzi in Europe
TipRanks 2d
Pfizer says EC grants marketing approval to expand indication for Hympavzi

Pfizer (PFE) announced that the European Commission has granted marketing authorization to expand the approved indication for Hympavzi to include patients 12 ye...

TipRanks 3d
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’

After Rigel Pharmaceuticals (RIGL) announced it has entered into an exclusive global licensing agreement with Pfizer (PFE) and Arvinas (ARVN) for Veppanu for th...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.